Difference between revisions of "Alectinib (Alecensa)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
Warner-admin (talk | contribs) m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Non-small_cell_lung_cancer | + | *[[Non-small_cell_lung_cancer,_ALK-positive|ALK+ non-small cell lung cancer]] |
==Patient drug information== | ==Patient drug information== | ||
| Line 16: | Line 16: | ||
==Also known as== | ==Also known as== | ||
| − | *AF802, AF-802, CH5424802, RG7853, RO5424802, UNII-LIJ4CT1Z3Y | + | *'''Code names:''' AF802, AF-802, CH5424802, RG7853, RO5424802, UNII-LIJ4CT1Z3Y |
| + | *'''Brand name:''' Alecensa | ||
==References== | ==References== | ||
| Line 22: | Line 23: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| Line 31: | Line 32: | ||
[[Category:Drugs FDA approved in 2015]] | [[Category:Drugs FDA approved in 2015]] | ||
| + | [[Category:FDA approved drugs]] | ||
Revision as of 16:00, 26 October 2017
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK). Alectinib and its metabolite M4 inhibit ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, which results in decreased growth of tumor cells which have ALK fusions, amplifications, or activating mutations.[1][2][3][4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 12/11/2015: Granted accelerated FDA approval "for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib."
Also known as
- Code names: AF802, AF-802, CH5424802, RG7853, RO5424802, UNII-LIJ4CT1Z3Y
- Brand name: Alecensa